FDA: GSK's Zofran might increase risk of abnormal heart rhythm

09/15/2011 | Wall Street Journal, The

The FDA is investigating the safety of GlaxoSmithKline's Zofran, or ondansetron, because of concern that the treatment increases the risk of abnormal heart rhythm. Zofran prevents nausea and vomiting in patients undergoing chemotherapy, surgery and radiotherapy. The FDA said it will add recommendations to Zofran's label, including electrocardiogram monitoring in certain patients.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT